Trial reportHypertension (Dallas, Tex. : 1979)2024
Relationship Between Sarcopenia and Intensive Blood Pressure Control Efficacy and Safety: A Secondary Analysis of SPRINT.
Trial report in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01206062 (Systolic Blood Pressure Intervention Trial), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Systolic Blood Pressure Intervention Trial
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between sarcopenia and atrial fibrillation: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Pathological changes and therapeutic strategies for sarcopenia.EFORT open reviews · 2026Review
- Sarcopenia in cognitive disorders: Toward a shared pathophysiological framework.Osteoporosis and sarcopenia · 2026Review
- Sarcopenia as a Prognostic Marker of Early Mortality After Surgery for Acute Aortic Dissection: A Prospective Cohort Study.Medical sciences (Basel, Switzerland) · 2026Article
- Mediation of fasting blood glucose between relative muscle strength and hypertension: insights from two cohorts.Diabetology & metabolic syndrome · 2025Article
- Monitoring Sarcopenia With Incretin Receptor Activator Treatment.Journal of diabetes · 2025Article
- Review of Blood Pressure Control in Vulnerable Older Adults: The Role of Frailty and Sarcopenia.Journal of vascular diseases · 2025Article
- Relationship between atherosclerotic burden and sarcopenia in U.S. adults: A cross-sectional study based on the NHANES database.Scientific reports · 2025Article
- Genomic medicine and personalized treatment: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Combining body mass index and muscle function in investigating mortality among older hypertensive patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Walking pace and its association with osteoporosis and pathological fractures: insights from UK biobank.Frontiers in endocrinology · 2025Article
- Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and sarcopenia based on NHANES.Scientific reports · 2024Article
- Sarcopenia as a risk factor for hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Sarcopenia.Journal of diabetes · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundSarcopenia and hypertension are independently associated with worse cardiovascular disease (CVD) risk and survival. While individuals with sarcopenia may benefit from intensive blood pressure (BP) control, the increased vulnerability of this population raises concerns for potential harm. This study aimed to evaluate clinical and safety outcomes with intensive (target <120 mm Hg) versus standard (<140 mm Hg) systolic BP targets in older hypertensive adults with sarcopenia compared with nonsarcopenic counterparts in the SPRINT (Systolic Blood Pressure Intervention Trial).
methodsSarcopenia was defined using surrogates of the lowest sex-stratified median of the sarcopenia index (serum creatinine/cystatin C×100) for muscle wasting and gait speed ≤0.8 m/s for muscle weakness. Outcomes included CVD events, all-cause mortality, and serious adverse events.
resultsOf 2571 SPRINT participants with sarcopenia index and gait speed data available (aged ≥75 years), 502 (19.5%) met the criteria for sarcopenia, which was associated with higher risks of CVD events (adjusted hazard ratio, 1.49 [95% CI, 1.15-1.94];
conclusionsOlder hypertensive adults with sarcopenia randomized to intensive BP control experienced a lower risk of CVD without increased adverse events compared with standard BP control. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01206062.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.